Pulmonology

Our top 5 headlines include a trial of gene-edited pig kidneys, a first-of-its-kind antibiotic approval, and new guidelines for migraine.

Approved under the name Dupixent in September 2024, the biologic is the first of its kind approved for COPD.

Brensocatib, also a potential first-in-class DPP1 inhibitor, has a PDUFA date of August 12, 2025.

Despite being aware of its value in treating asthma, specialists were uncertain about integrating ITT into patient care.

In a Q&A, Kang discusses the role of MAVS in host resilience, aging as a contributing factor of lung disease, and the link between viral innate immunity and aging biology.

This pulmonology month in review highlights recent research on diagnosing asthma and new pivotal trial data.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

Merck announced robust efficacy data on the benefit of sotatercept for PAH in the STELLAR and ZENITH studies led to a loss of clinical equipoise in HYPERION.

Frevecitinib is a novel inhaled dry powder therapeutic in development for asthma that remains inadequately controlled by SOC inhaled maintenance therapies.

The study also revealed a predominant T2-low asthma endotype in majority Puerto Rican and Black or African American youth populations.

This month’s Lungcast features a discussion on pulmonary function tests and the controversial practice of using race-based normal values.

However, subgroup analyses may reveal a more pronounced effect in people with severe COPD.

CRN declined from 23.2% to 13.1% between 2011 and 2022 but still affects around 2.5 million adults in the US.

New findings cast doubt on required black box warnings for montelukast (brand name Singulair).

Meteorological conditions’ effect on exacerbations were likely mediated by particulate matter.

In this summary, we highlight the latest issue of our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

This interview in the latest issue of The Respiratory Report features Stephen Schworer, Md, PhD, discussing the role of mucus plugging in severe asthma.

Exploring mucus plugging in severe asthma, focusing on small airway dysfunction, MUC5AC expression, and epithelial heterogeneity using advanced methods.

Joselyn Rojas-Quintero, MD, speaks about her team's current research into COPD treatment on this issue of The Respiratory Report.

The importance of AT2 cells in repairing injured alveoli and maintaining alveoli number and lumen size suggests that COPD therapies may be implemented to improve AT2 cell biology and/or increase AT2 cell numbers.

Abebaw Yohannes, MSc, PhD, speaks about his team’s pilot study designed to assess the use of duloxetine for patients with COPD and comorbid depression.

Pilot study tests duloxetine’s feasibility for depression in COPD, examining patient/physician attitudes, treatment barriers, and therapy effects.

The RECEIVE study develops tools to standardize returning chest CT results in the Lung Health Cohort, improving engagement and ethical practices.

Medicare has selected 15 additional drugs to negotiate prices directly with participating drug companies, including semaglutide (Ozempic).